Phaseline

Targets › AMPK

AMPK (5'-AMP-activated protein kinase catalytic subunit alpha-2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Other.

Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. (UniProt, P54646)

Open in Phaseline: the race on AMPK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Intervene ImmuneTRIIM Treatment
Combination of somatropin (recombinant human growth hormone), metformin, and DHEA
GH1, AMPKPhase 2Epigenetic Aging–

Conditions

Epigenetic Aging (1)

Modalities

–

Companies

Intervene Immune (1)

Related targets

GH1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.